Overall, by down-regulating the PDGF-β, metformin seems to inhibit excessive angiogenesis characteristics of metastatic tumors and improve vascular functionality, which, in turn, results in improved delivery of other chemotherapeutic drugs. Here, PDGFB is linked to metastatic neoplasm.